Literature DB >> 28964908

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

David Y Graham1, Aylin Tansel2.   

Abstract

Although proton pump inhibitors (PPIs) are widely used, their relative potency and ideal dosing regimens remain unclear. We analyzed data from randomized clinical trials that performed pH testing in patients receiving solid-dose PPI formulations (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) for a minimum of 5 days. We used omeprazole equivalency and the surrogate biomarker, percentage time pH > 4 over a 24-hour period (pH4time), to compare PPI effectiveness for different PPIs given once, twice, or 3 times daily. We found that increasing strength of once-daily PPIs (9-64 mg omeprazole equivalents) increased pH4time linearly from approximately 10.0 to 15.6 hours; higher doses produced no further increase in pH4time. Increasing the frequency to twice-daily PPI increased pH4time linearly, from approximately 15.8 to 21.0 hours. Three-times daily PPIs performed similarly to twice-daily PPIs. The costs of PPIs varied greatly, but the cost variation was not directly related to potency. We conclude that PPIs can be used interchangeably based on potency. Using twice-daily PPIs is more effective in increasing efficacy increasing once-daily PPI dosage. Omeprazole and lansoprazole (30 mg) and 20 mg of esomeprazole rabeprazole are functionally equivalent.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug; Efficacy Comparison; GERD; Reflux; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28964908      PMCID: PMC6913203          DOI: 10.1016/j.cgh.2017.09.033

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  47 in total

1.  Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.

Authors:  Anton Pottegård; Anne Broe; Jesper Hallas; Ove B Schaffalitzky de Muckadell; Annmarie T Lassen; Anders B Lødrup
Journal:  Therap Adv Gastroenterol       Date:  2016-05-26       Impact factor: 4.409

2.  Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

Authors:  D B Jones; C W Howden; D W Burget; G D Kerr; R H Hunt
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

3.  Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.

Authors:  H Koop; S Kuly; M Flüg; R Eissele; H Mönnikes; K Rose; R Lühmann; A Schneider; R Fischer; R Arnold
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-09       Impact factor: 2.566

4.  Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.

Authors:  C Florent; S Forestier
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-02       Impact factor: 2.566

Review 5.  Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004.

Authors:  David Armstrong; John K Marshall; Naoki Chiba; Robert Enns; Carlo A Fallone; Ronnie Fass; Roger Hollingworth; Richard H Hunt; Peter J Kahrilas; Serge Mayrand; Paul Moayyedi; William G Paterson; Dan Sadowski; Sander Jo Veldhuyzen van Zanten
Journal:  Can J Gastroenterol       Date:  2005-01       Impact factor: 3.522

6.  Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.

Authors:  R Tutuian; P O Katz; W Bochenek; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

7.  Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial.

Authors:  Lars Lundell; Jan Hatlebakk; Jean-Paul Galmiche; Stephen E Attwood; Christian Ell; Roberto Fiocca; Tore Persson; Péter Nagy; Stefan Eklund; Tore Lind
Journal:  Curr Med Res Opin       Date:  2014-10-31       Impact factor: 2.580

8.  Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.

Authors:  Y Sakurai; Y Mori; H Okamoto; A Nishimura; E Komura; T Araki; M Shiramoto
Journal:  Aliment Pharmacol Ther       Date:  2015-07-21       Impact factor: 8.171

9.  The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers.

Authors:  C Wilder-Smith; K Röhss; S Bokelund Singh; M Sagar; P Nagy
Journal:  Aliment Pharmacol Ther       Date:  2010-09-29       Impact factor: 8.171

10.  Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.

Authors:  H Jenkins; Y Sakurai; A Nishimura; H Okamoto; M Hibberd; R Jenkins; T Yoneyama; K Ashida; Y Ogama; S Warrington
Journal:  Aliment Pharmacol Ther       Date:  2015-02-23       Impact factor: 8.171

View more
  21 in total

1.  Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).

Authors:  Abhijeet Waghray; Nisheet Waghray; Adam T Perzynski; Mark Votruba; M Michael Wolfe
Journal:  Dig Dis Sci       Date:  2018-08-09       Impact factor: 3.199

2.  Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.

Authors:  David Y Graham; Hong Lu; Maria Pina Dore
Journal:  Helicobacter       Date:  2018-11-15       Impact factor: 5.753

3.  Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.

Authors:  Luyi Chen; Jiamin He; Lan Wang; Qiwei Ge; Hua Chu; Yujia Chen; Xiaoli Chen; Yanqin Long; Yanyong Deng; Huiqin He; Aiqing Li; Shujie Chen
Journal:  Clin Exp Med       Date:  2018-06-06       Impact factor: 3.984

Review 4.  Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy.

Authors:  David Y Graham; Theodore Rokkas; Ruben Hernaez
Journal:  Gut       Date:  2021-11-08       Impact factor: 23.059

Review 5.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

Authors:  Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

6.  Type of proton-pump inhibitor and risk of iron deficiency in kidney transplant recipients - results from the TransplantLines Biobank and Cohort Study.

Authors:  Rianne M Douwes; Joanna Sophia J Vinke; António W Gomes-Neto; Gizem Ayerdem; Gaston van Hassel; Stefan P Berger; Daan J Touw; Hans Blokzijl; Stephan J L Bakker; Martin H de Borst; Michele F Eisenga
Journal:  Transpl Int       Date:  2021-10-07       Impact factor: 3.842

7.  Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis.

Authors:  Kisan P Thakkar; Mark Fowler; Staci Keene; Alina Iuga; Evan S Dellon
Journal:  Dig Liver Dis       Date:  2022-04-08       Impact factor: 5.165

Review 8.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 9.  Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain.

Authors:  Gyanprakash A Ketwaroo; David Y Graham
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

10.  Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?

Authors:  Kristin M Aasarød; Mats P Mosti; Malin T Finstad; Astrid K Stunes; Reidar Fossmark; Unni Syversen
Journal:  Bone Rep       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.